BMS-986353

Phase 3Small molecule

JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

BMS-986353 is one of 73 small molecule programs targeting Systemic Sclerosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic SclerosisActive, not recruiting

Immune ThrombocytopeniaNot yet recruiting

Systemic SclerosisPhase 3

Active, not recruiting

Immune ThrombocytopeniaPhase 2

Not yet recruiting

Competition

Competitive Landscape

165 competitors in Systemic Sclerosis

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

3 2

Actemra

Roche

Phase 3

3 3

Medrol

Pfizer

Phase 3

3 4

Opsumit

Johnson & Johnson

Phase 3

2 5

Rinvoq

AbbVie

Phase 3

1 6

Cysteine Hydrochloride

Novartis

Phase 3

1 7

Neupogen

EEastern Cooperative Oncology Group

Phase 3

1 8

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 9

Ofev

Boehringer Ingelheim

Phase 3

1 10

Esbriet

LLegacy Health System

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2Not yet recruiting

Immune Thrombocytopenia

NCT07603557

Q4 2030

Phase 3Not yet recruiting

Systemic Sclerosis

NCT07335562

Clinical

Trials by Indication[1]

Systemic Sclerosis1 trial

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

Not yet recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 3·NCT07335562·92 enrolled

Immune Thrombocytopenia1 trial

A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA)

Not yet recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 2·NCT07603557·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BMS-986353. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-986353 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-986353. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Juno Therapeutics, Inc., a Bristol-Myers Squibb Company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

BMS-986353

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Q4 2030

Trials by Indication[1]

Systemic Sclerosis1 trial

Immune Thrombocytopenia1 trial

References

Drug Info

Quick Facts

Related News